Steven Lo, CEO of Zosano Pharma
After culling workforce, migraine biotech Zosano drops lead — and sole — program
It appears Zosano may not have much left in the tank.
In April, the migraine-focused biotech announced that it would cull about a third of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
